Lifevantage Corp (LFVN) stock
Close on Nov 12, 2026Market cap $63.14MP/E 24.0Yield 3.67%
Lifevantage Corp saw revenue fall 24.8% to $172.14M over the twelve months to Sep 30, 2026. Operating income fell 68.9% to $3.70M, moving the operating margin from 5.2% to 2.1%. Free cash flow was $8.71M, up 0.1% from a year earlier. At the latest close the market valued the company at $63.14M, 24.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $63.14M
- P/E ratio
- 24.0
- Price to sales
- 0.37
- Price to book
- 1.90
- Dividend yield
- 3.67%
- Free cash flow yield
- 13.79%
Fundamentals
- Revenue
- $172.14M
- Net income
- $2.72M
- EPS, diluted
- $0.21
- Free cash flow
- $8.71M
- Book value per share
- $2.67
- Diluted shares
- 12M
Trading
- Next earnings
- Feb 3, 2027 (estimated, after the close)
- Previous close
- $4.72
- Open
- $4.87
- Day's range
- $4.72 – $5.25
- Volume
- 183,641
- Average volume (20 days)
- 33,719
- Beta (5 years)
- 0.38
- 52-week range
- $3.90 – $11.71
- RSI (14 days)
- 29.2
- Volatility (1 year)
- 74.9%
- Relative volume
- 1.05×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LFVN | S&P 500 | Difference | LFVN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.7% | -2.7% | −13.0 pts | ||
| 3 months | -22.0% | -1.7% | −20.2 pts | ||
| Year to date | -16.2% | +11.9% | −28.1 pts | ||
| 1 year | -21.7% | +12.0% | −33.7 pts | ||
| 3 years | -5.7% | +78.2% | −83.9 pts | -1.9% | +21.2% |
| 5 years | -17.2% | +73.2% | −90.4 pts | -3.7% | +11.6% |
| 10 years | -22.4% | +309.6% | −332.0 pts | -2.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lifevantage filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Lifevantage
Pharmaceutical Preparations
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, weight management and gut health products, nootropics, and personal care items. Its principal offerings include Protandim dietary supplements, TrueScience skin and hair care products, the MindBody GLP-1 and Rise AM & Reset PM systems, AXIO drink mixes, and Petandim companion pet supplements. The company distributes its products through a network marketing direct sales model, utilizing independent consultants as well as direct consumer transactions and subscription programs.
Company profile, executives and historyLifevantage stock: common questions
What is Lifevantage's stock price?
LFVN closed at $5.04 on Nov 12, 2026, up 6.78% on the day. Over the past 52 weeks it traded between $3.90 and $11.71.
What is Lifevantage's market cap?
Lifevantage was worth $63.14M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LFVN's P/E ratio?
LFVN trades at 24.0 times earnings, based on diluted earnings per share of $0.21 over the twelve months to Sep 30, 2026.
How much revenue does Lifevantage make?
Lifevantage reported revenue of $172.14M for the twelve months to Sep 30, 2026, down 24.8% from a year earlier.
Does Lifevantage pay a dividend?
Yes. Lifevantage paid $0.18 per share over the last twelve months, a yield of 3.67% at the latest price.
When does Lifevantage report earnings next?
Lifevantage is expected to report Q2 FY2027 results on Feb 3, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has LFVN stock performed over the past year?
Including dividends, LFVN returned -21.7% over the past year, against +12.0% for the S&P 500.
How many LFVN shares are sold short?
1M shares were sold short at the latest FINRA report, 10.03% of the float, or 42.1 days of average trading volume.
Who are Lifevantage's competitors?
Companies most similar to Lifevantage by business, industry and size include NATR, PRE, LGND, AMRN, MTEX.
See a number that looks wrong?